Literature DB >> 2526817

Detection of fms-oncogene-specific tyrosine kinase activity in human leukemia cells.

T Tamura1, H Brost, A Käbisch, F Lampert, A Hadwiger-Fangmeier, H Niemann.   

Abstract

The c-fms protooncogene encodes the receptor for the colony-stimulating factor 1 of macrophages. Its transforming counterpart, the v-fms oncogene has previously been recognized as the transforming gene of the McDonough strain of feline sarcoma virus. We have isolated rabbit antisera against a 115-kDa recombinant polypeptide containing the 926 carboxy-terminal amino acids of the v-fms protein. All antibodies recognized the cytoplasmic domain of the v-fms protein, which is 95% homologous to the corresponding domain of human c-fms proteins. These sera were applied in a survey of various human cancer cell lines, such as peripheral blood mononuclear (HL60) and choriocarcinoma (BeWo) cells, as well as leukemic cells from 58 patients with acute myelocytic, chronic myelocytic or acute lymphocytic leukemias (AML, CML, ALL). Significantly enhanced levels of fms-specific tyrosine kinase activity were detected in 12-O-tetradecanoylphorbol-13-acetate-induced HL60 and in BeWo cells, and in 7 out of 24 samples from AML patients, whereas no activity could be detected in 9 ALL or in 25 CML cell preparations. The AML cells were classified according to the FAB criteria. The highest incidence of increased fms activity was found in cells assigned to the M4 class (four out of five cases). While no activity was found in material belonging to FAB classes M2 or M3, one of the two cases of the M5 class was kinase-positive. Interestingly, two out of seven cases of the M1 class cells exhibited enhanced levels of fms kinase. These data suggest that the determination of the fms kinase may be useful to subdivide the M1 class of the FAB classification into monocytic and non-monocytic precursor leukemia cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2526817     DOI: 10.1007/bf00391695

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  22 in total

1.  Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype.

Authors:  J Woolford; A McAuliffe; L R Rohrschneider
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

2.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

3.  Expression of the c-fms proto-oncogene during human monocytic differentiation.

Authors:  E Sariban; T Mitchell; D Kufe
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

4.  Expression of the human c-fms proto-oncogene in hematopoietic cells and its deletion in the 5q- syndrome.

Authors:  A W Nienhuis; H F Bunn; P H Turner; T V Gopal; W G Nash; S J O'Brien; C J Sherr
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

5.  Nucleotide sequence of the feline retroviral oncogene v-fms shows unexpected homology with oncogenes encoding tyrosine-specific protein kinases.

Authors:  A Hampe; M Gobet; C J Sherr; F Galibert
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

6.  Characterization of the human c-fms gene product and its expression in cells of the monocyte-macrophage lineage.

Authors:  J Woolford; V Rothwell; L Rohrschneider
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

7.  Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders.

Authors:  M M Le Beau; C A Westbrook; M O Diaz; R A Larson; J D Rowley; J C Gasson; D W Golde; C J Sherr
Journal:  Science       Date:  1986-02-28       Impact factor: 47.728

8.  Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells.

Authors:  A Rambaldi; N Wakamiya; E Vellenga; J Horiguchi; M K Warren; D Kufe; J D Griffin
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

9.  Transcription of c-onc genes c-rasKi and c-fms during mouse development.

Authors:  R Müller; D J Slamon; E D Adamson; J M Tremblay; D Müller; M J Cline; I M Verma
Journal:  Mol Cell Biol       Date:  1983-06       Impact factor: 4.272

10.  Appropriate glycosylation of the fms gene product is a prerequisite for its transforming potency.

Authors:  A Hadwiger; H Niemann; A Käbisch; H Bauer; T Tamura
Journal:  EMBO J       Date:  1986-04       Impact factor: 11.598

View more
  2 in total

1.  Tyrosine 807 of the v-Fms oncogene product controls cell morphology and association with p120RasGAP.

Authors:  S Trouliaris; U Smola; J H Chang; S J Parsons; H Niemann; T Tamura
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

Review 2.  Hotspots of MLV integration in the hematopoietic tumor genome.

Authors:  T Tsuruyama; T Hiratsuka; N Yamada
Journal:  Oncogene       Date:  2016-11-07       Impact factor: 9.867

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.